CJC-1295 / FAQ
CJC-1295: direct answers to the questions people actually ask.
Safety, regulatory status, the steroid question, testosterone, and the ipamorelin pairing — answered from the published record, with the gaps flagged where the evidence runs out.
Why is CJC-1295 often paired with ipamorelin?
GHRH analogs and GHRPs act through distinct receptors and synergize: co-administration produces GH release greater than the sum of either alone, the mechanistic rationale for pairing CJC-1295 with a selective GHRP such as ipamorelin [8]. CJC-1295 supplies the sustained GHRH-receptor stimulus while ipamorelin adds a separate ghrelin-receptor signal [9].
Does CJC-1295 preserve the natural pulse pattern of growth hormone?
In healthy men, a single dose raised basal GH about 7.5-fold and IGF-1 about 45% one week later while the frequency and magnitude of pulsatile GH secretion were unaltered, indicating pulsatility persists under continuous GHRH-analog stimulation [3]. The sustained baseline rose without flattening the pulse train [3].
What is CJC-1295?
A synthetic long-acting analog of growth-hormone-releasing hormone, built on hGRF(1-29) with four protease-resistant substitutions; the DAC variant adds covalent serum-albumin conjugation for a multi-day half-life, while the no-DAC form is short-acting [2]. It acts on the pituitary GHRH receptor to stimulate GH release [3].
What does CJC-1295 do?
It binds the GHRH receptor on pituitary somatotrophs, stimulating pulsatile growth-hormone release and a downstream rise in hepatic IGF-1; in human PK studies it elevated GH and IGF-1 for days after a single dose [1][3]. Basal GH rose about 7.5-fold and IGF-1 about 45% at one week [3].
Is CJC-1295 safe?
There are no large efficacy or long-term safety trials in healthy adults; CJC-1295 is an unapproved research chemical [1]. Theoretical concerns include fluid retention from GH-axis stimulation and the epidemiologic link between higher IGF-1 and a modestly increased risk of some cancers. The published safety database is thin and short-term.
How much CJC-1295 should I take?
Human PK studies used single subcutaneous doses of 30, 60, or 90 micrograms per kilogram in healthy adults; community "protocols" citing fixed 100-to-300-microgram doses are not derived from controlled human trials [1][3]. This site reports studied doses, not human recommendations, and CJC-1295 is an unapproved research chemical.
How much CJC-1295 DAC should I take?
The DAC variant's multi-day half-life of 5.8 to 8.1 days is why its dosing schedule differs from the short-acting no-DAC form; published human PK work used 30-to-90-microgram-per-kilogram single subcutaneous doses [1][3]. No human dose is endorsed here.
What is CJC-1295 with DAC?
DAC ("Drug Affinity Complex") is a maleimide chemistry that covalently links the peptide to circulating serum albumin, extending its plasma half-life toward that of albumin and giving CJC-1295 DAC a multi-day duration of action [2]. The C-terminal handle binds the free thiol on albumin's Cys34, forming a stable peptide-albumin conjugate [2].
What is CJC-1295 DAC?
CJC-1295 DAC is the albumin-conjugated, long-acting form of the tetrasubstituted GHRH(1-29) analog; in rats it raised GH area-under-the-curve 4-fold over unconjugated peptide and remained detectable in plasma beyond 72 hours [2]. In healthy adults its estimated half-life is 5.8 to 8.1 days [1].
How to reconstitute CJC-1295?
In research handling the lyophilized peptide is reconstituted with bacteriostatic water and refrigerated; oral bioavailability is negligible because it is a peptide [2]. Handling notes describe laboratory practice, not human-use instructions, and CJC-1295 is not approved for human use.
Is CJC-1295 a steroid?
No. CJC-1295 is a peptide GHRH analog that acts upstream on the pituitary to stimulate growth-hormone release; it is not an anabolic-androgenic steroid and works through an entirely different receptor system [3]. Its target is the GHRH receptor, not an androgen or steroid-hormone receptor [2].
Where to inject CJC-1295?
Published pharmacokinetic studies administered CJC-1295 by subcutaneous injection [1]. This describes the route used in research; it is not guidance for human use of an unapproved compound.
Is CJC-1295 FDA approved?
No. CJC-1295 is not approved by the FDA or any major regulator for human use; it is sold and handled as a research chemical and was not recommended for the 503A compounding bulks list at the 2024 FDA Pharmacy Compounding Advisory Committee. It is also prohibited at all times in sport under WADA Section S2.
How much CJC-1295 / ipamorelin should I take?
The pairing rests on a two-receptor synergy rationale, but combined fixed-dose "protocols" online are not derived from controlled human trials [8]. Published CJC-1295 PK work used 30-to-90-microgram-per-kilogram subcutaneous doses [1]; no human dose is endorsed here.
Does CJC-1295 and ipamorelin work?
Mechanistically, GHRH analogs and GHRPs co-administered produce supra-additive GH release; ipamorelin is a selective GH secretagogue [8]. Direct controlled human-outcome trials of the specific combination are limited, so claims about body-composition results outrun the published evidence [10].
What is CJC-1295 ipamorelin?
It refers to combining the GHRH analog CJC-1295 with ipamorelin, a selective growth-hormone secretagogue, so that two distinct GH-release pathways are stimulated together — a common research pairing, not a single compound [8]. They are separate molecules with separate receptors [9].
Are CJC-1295 peptides safe?
The peer-reviewed safety database in healthy adults is thin and short-term [1]. GH-axis stimulation can cause sodium retention and edema, and the development-era DAC program was discontinued; CJC-1295 remains unapproved for human use. Controlled long-term safety data are not available.
Does CJC affect testosterone?
CJC-1295 acts on the GH/IGF-1 axis, not the gonadal axis; the published literature on the peptide does not establish a direct effect on testosterone [3]. Claims either way go beyond the controlled human data available. Its documented action is on GH release and IGF-1, a separate hormonal system.
What are the side effects of CJC-1295?
Reported and theoretical concerns include fluid retention and edema from GH-driven sodium reabsorption, effects on insulin sensitivity, immunogenicity (flagged by FDA in 2024), and the epidemiologic IGF-1/cancer-risk signal; controlled long-term safety data are lacking [1]. None of these are from a long-term safety trial, because none exists.
What to expect when taking CJC-1295?
In human PK studies, a single dose produced a sustained, days-long rise in GH and IGF-1 while preserving GH pulsatility [1][3]. Because CJC-1295 is unapproved with limited human data, this describes measured physiology, not promised outcomes. The published readouts are endocrine and pharmacokinetic, not body-composition.
Does CJC-1295 lower testosterone?
Nothing in the published CJC-1295 literature establishes that it lowers testosterone; the peptide's documented action is on GH/IGF-1, a separate axis [3]. Statements of a testosterone effect are not supported by controlled human data. The GH axis and the gonadal axis are distinct systems.
Are peptides safer than TRT?
This is not answerable from the CJC-1295 evidence base: testosterone replacement is an approved therapy with decades of data, whereas CJC-1295 is an unapproved peptide with only early PK studies [1]. The two are not comparable on safety from the published record, and no head-to-head data exist.